259 related articles for article (PubMed ID: 25978431)
21. The NPM-ALK oncoprotein abrogates CD30 signaling and constitutive NF-kappaB activation in anaplastic large cell lymphoma.
Horie R; Watanabe M; Ishida T; Koiwa T; Aizawa S; Itoh K; Higashihara M; Kadin ME; Watanabe T
Cancer Cell; 2004 Apr; 5(4):353-64. PubMed ID: 15093542
[TBL] [Abstract][Full Text] [Related]
22. Proteome-wide identification of novel binding partners to the oncogenic fusion gene protein, NPM-ALK, using tandem affinity purification and mass spectrometry.
Wu F; Wang P; Young LC; Lai R; Li L
Am J Pathol; 2009 Feb; 174(2):361-70. PubMed ID: 19131589
[TBL] [Abstract][Full Text] [Related]
23. Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency.
Ceccon M; Merlo MEB; Mologni L; Poggio T; Varesio LM; Menotti M; Bombelli S; Rigolio R; Manazza AD; Di Giacomo F; Ambrogio C; Giudici G; Casati C; Mastini C; Compagno M; Turner SD; Gambacorti-Passerini C; Chiarle R; Voena C
Oncogene; 2016 Jul; 35(29):3854-3865. PubMed ID: 26657151
[TBL] [Abstract][Full Text] [Related]
24. NPM-ALK phosphorylates WASp Y102 and contributes to oncogenesis of anaplastic large cell lymphoma.
Murga-Zamalloa CA; Mendoza-Reinoso V; Sahasrabuddhe AA; Rolland D; Hwang SR; McDonnell SR; Sciallis AP; Wilcox RA; Bashur V; Elenitoba-Johnson K; Lim MS
Oncogene; 2017 Apr; 36(15):2085-2094. PubMed ID: 27694894
[TBL] [Abstract][Full Text] [Related]
25. Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.
Ceccon M; Mologni L; Giudici G; Piazza R; Pirola A; Fontana D; Gambacorti-Passerini C
Mol Cancer Res; 2015 Apr; 13(4):775-83. PubMed ID: 25421750
[TBL] [Abstract][Full Text] [Related]
26. Sonic hedgehog signaling pathway is activated in ALK-positive anaplastic large cell lymphoma.
Singh RR; Cho-Vega JH; Davuluri Y; Ma S; Kasbidi F; Milito C; Lennon PA; Drakos E; Medeiros LJ; Luthra R; Vega F
Cancer Res; 2009 Mar; 69(6):2550-8. PubMed ID: 19244133
[TBL] [Abstract][Full Text] [Related]
27. The anaplastic lymphoma kinase controls cell shape and growth of anaplastic large cell lymphoma through Cdc42 activation.
Ambrogio C; Voena C; Manazza AD; Martinengo C; Costa C; Kirchhausen T; Hirsch E; Inghirami G; Chiarle R
Cancer Res; 2008 Nov; 68(21):8899-907. PubMed ID: 18974134
[TBL] [Abstract][Full Text] [Related]
28. Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphoma.
Zhang Q; Raghunath PN; Xue L; Majewski M; Carpentieri DF; Odum N; Morris S; Skorski T; Wasik MA
J Immunol; 2002 Jan; 168(1):466-74. PubMed ID: 11751994
[TBL] [Abstract][Full Text] [Related]
29. Nucleophosmin-anaplastic lymphoma kinase of large-cell anaplastic lymphoma is a constitutively active tyrosine kinase that utilizes phospholipase C-gamma to mediate its mitogenicity.
Bai RY; Dieter P; Peschel C; Morris SW; Duyster J
Mol Cell Biol; 1998 Dec; 18(12):6951-61. PubMed ID: 9819383
[TBL] [Abstract][Full Text] [Related]
30. HuR-mediated control of C/EBPbeta mRNA stability and translation in ALK-positive anaplastic large cell lymphomas.
Bergalet J; Fawal M; Lopez C; Desjobert C; Lamant L; Delsol G; Morello D; Espinos E
Mol Cancer Res; 2011 Apr; 9(4):485-96. PubMed ID: 21343335
[TBL] [Abstract][Full Text] [Related]
31. Serine phosphorylation of NPM-ALK, which is dependent on the auto-activation of the kinase activation loop, contributes to its oncogenic potential.
Wang P; Wu F; Zhang J; McMullen T; Young LC; Ingham RJ; Li L; Lai R
Carcinogenesis; 2011 Feb; 32(2):146-53. PubMed ID: 21045017
[TBL] [Abstract][Full Text] [Related]
32. NPM-ALK and the JunB transcription factor regulate the expression of cytotoxic molecules in ALK-positive, anaplastic large cell lymphoma.
Pearson JD; Lee JK; Bacani JT; Lai R; Ingham RJ
Int J Clin Exp Pathol; 2011 Jan; 4(2):124-33. PubMed ID: 21326808
[TBL] [Abstract][Full Text] [Related]
33. The proteomic signature of NPM/ALK reveals deregulation of multiple cellular pathways.
Lim MS; Carlson ML; Crockett DK; Fillmore GC; Abbott DR; Elenitoba-Johnson OF; Tripp SR; Rassidakis GZ; Medeiros LJ; Szankasi P; Elenitoba-Johnson KS
Blood; 2009 Aug; 114(8):1585-95. PubMed ID: 19531656
[TBL] [Abstract][Full Text] [Related]
34. Constitutive activation of Jak2 contributes to proliferation and resistance to apoptosis in NPM/ALK-transformed cells.
Ruchatz H; Coluccia AM; Stano P; Marchesi E; Gambacorti-Passerini C
Exp Hematol; 2003 Apr; 31(4):309-15. PubMed ID: 12691918
[TBL] [Abstract][Full Text] [Related]
35. p130Cas mediates the transforming properties of the anaplastic lymphoma kinase.
Ambrogio C; Voena C; Manazza AD; Piva R; Riera L; Barberis L; Costa C; Tarone G; Defilippi P; Hirsch E; Boeri Erba E; Mohammed S; Jensen ON; Palestro G; Inghirami G; Chiarle R
Blood; 2005 Dec; 106(12):3907-16. PubMed ID: 16105984
[TBL] [Abstract][Full Text] [Related]
36. Loss of SHP1 enhances JAK3/STAT3 signaling and decreases proteosome degradation of JAK3 and NPM-ALK in ALK+ anaplastic large-cell lymphoma.
Han Y; Amin HM; Franko B; Frantz C; Shi X; Lai R
Blood; 2006 Oct; 108(8):2796-803. PubMed ID: 16825495
[TBL] [Abstract][Full Text] [Related]
37. The expression of CD30 in anaplastic large cell lymphoma is regulated by nucleophosmin-anaplastic lymphoma kinase-mediated JunB level in a cell type-specific manner.
Hsu FY; Johnston PB; Burke KA; Zhao Y
Cancer Res; 2006 Sep; 66(18):9002-8. PubMed ID: 16982741
[TBL] [Abstract][Full Text] [Related]
38. Expression of the oncogenic NPM-ALK chimeric protein in human lymphoid T-cells inhibits drug-induced, but not Fas-induced apoptosis.
Greenland C; Touriol C; Chevillard G; Morris SW; Bai R; Duyster J; Delsol G; Allouche M
Oncogene; 2001 Nov; 20(50):7386-97. PubMed ID: 11704868
[TBL] [Abstract][Full Text] [Related]
39. Lobatin B inhibits NPM/ALK and NF-κB attenuating anaplastic-large-cell-lymphomagenesis and lymphendothelial tumour intravasation.
Kiss I; Unger C; Huu CN; Atanasov AG; Kramer N; Chatruphonprasert W; Brenner S; McKinnon R; Peschel A; Vasas A; Lajter I; Kain R; Saiko P; Szekeres T; Kenner L; Hassler MR; Diaz R; Frisch R; Dirsch VM; Jäger W; de Martin R; Bochkov VN; Passreiter CM; Peter-Vörösmarty B; Mader RM; Grusch M; Dolznig H; Kopp B; Zupko I; Hohmann J; Krupitza G
Cancer Lett; 2015 Jan; 356(2 Pt B):994-1006. PubMed ID: 25444930
[TBL] [Abstract][Full Text] [Related]
40. EBP2, a novel NPM-ALK-interacting protein in the nucleolus, contributes to the proliferation of ALCL cells by regulating tumor suppressor p53.
Uchihara Y; Tago K; Tamura H; Funakoshi-Tago M
Mol Oncol; 2021 Jan; 15(1):167-194. PubMed ID: 33040459
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]